Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ru...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2017-08, Vol.130 (9), p.1125-1131
Main Authors: Newberry, Kate J., Patel, Keyur, Masarova, Lucia, Luthra, Rajyalakshmi, Manshouri, Taghi, Jabbour, Elias, Bose, Prithviraj, Daver, Naval, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Clonal Evolution
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Myeloid Neoplasia
Primary Myelofibrosis - drug therapy
Primary Myelofibrosis - genetics
Primary Myelofibrosis - pathology
Pyrazoles - therapeutic use
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2017-05-783225